Frustrated, there is a clear, distinction here:
BOD Eric Swartz helped save the company and would current shareholders rather go bankrupt or have someone such as Eric Swartz step in to put up his own money and financial backing? I'll take the support from Eric Swartz...vs financial distress of years past. Peregrine is in the strongest position ever at this point with Phase III and $60M+ in the bank and more on the way.
Now for the distinction, "ALL OTHER" small biotechs came in early and cave in big time, as they accept money from BP's and guess what they do ?? they are forced to accept BP affiliates onto their BOD.
Now stop for a second and think about this, you're going to say well that is what Peregrine did as they left financial distress behind and welcomed someone who seen the big future in Bavituximab, but that shows on their current BOD.
Next is the most important of them all, because all the former small biotechs that accepted Big Pharma money and accepted their additions to their respective Boards are also bought out for much less than what they are worth due to the very same added BP affiliate Board Members !!!
Think frustrated.. think.. think... think that concept through and when you can think clearly, just know that the added BOD to Peregrine are not BP affiliates and not going to side with a BP low price offer and absolutely going to maximize shareholder value for all shareholders.
I hope everyone can see this, because that is how Big Pharma seems to have worked all these years and the sabotage ? Well...now we know possibly why, because Peregrine was not selling out cheaply so what did Big Pharma have as their only alternative ??
Further proof would be any offer Peregrine received after the sabotage ( before the BP knew Peregrine would find out and discover the sabotage ) and the FDA would never allow this info to become public if that is the way it went down.
Further proof to possibly persuade some, would be how many other small biotechs have had their Phase III NSCLC approved off of combined data such as on the phase IIb NSCLC????? Absolutely NONE!
Why? .... maybe it fits or maybe it does not ... but Peregrine certainly seems to have more than 4 Aces in their back pocket and silently moving forward with no doubt that Bavituximab works and works quite well.
One will not find a puzzle like this in many places of the world, but it sure does seem like Phosphatidylserine is moving up fast on the charts for the target of all targets and that my friends... will eventually become well known as a blood based biomarker.
Not just oncology .. exists in humans, plants and animals and will MRI machines be upgraded globally as well? possibly
News 
Market Data 
Discover 
